title: New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir.
abstract: Hepatitis C is a chronic infection associated with considerable morbidity and mortality. In recent years, there has been a shift in treatment paradigm with the discovery and approval of agents that target specific proteins vital for hepatitis C replication. The NS3/4A inhibitors simeprevir and paritaprevir, the NS5A inhibitors ombitasvir, ledipasvir, and daclatasvir, and the NS5B inhibitors sofosbuvir and dasabuvir have been newly FDA approved and incorporated as first-line agents into the latest IDSA-AASLD guidelines for Hepatitis C treatment. Used in combination, these agents produce higher rates of sustained virologic response and less adverse effects than historical options, along with limited rates of resistance. Pertinent clinical data, pharmacology, and pharmacokinetics are reviewed for these new direct acting antiviral agents.
authors.affiliation: a Department of Pharmacy , Dekalb Medical Center , Decatur , GA , USA.
authors.forename: Sean M
authors.initials: SM
authors.lastname: McConachie
authors.affiliation: b Department of Pharmacy Practice , Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University , Detroit , MI , USA.|c Department of Pharmacy , Harper University Hospital , Detroit , MI , USA.
authors.forename: Sheila M
authors.initials: SM
authors.lastname: Wilhelm
authors.affiliation: b Department of Pharmacy Practice , Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University , Detroit , MI , USA.|d Department of Pharmacy Services , St. John Hospital and Medical Center , Detroit , MI , USA.
authors.forename: Pramodini B
authors.initials: PB
authors.lastname: Kale-Pradhan
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D017277:Drug Approval; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D017410:Practice Guidelines as Topic; D014779:Virus Replication / Q000187:drug effects
chemical_list: D000998:Antiviral Agents
keywords: Hepatitis C; daclatasvir; dasabuvir; ledipasvir; ombitasvir; paritaprevir; simeprevir; sofosbuvir; sustained virologic response; virologic relapse